Podcasts about Cart

Blood Cancer Talks — Show NotesEpisode: Best of ASCO/EHA 2026 — Multiple Myeloma & AL AmyloidosisGuest: Dr. Prashant Kapoor, MD Professor of Medicine, Mayo Clinic, Rochester, MN Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo ClinicEpisode OverviewIn this episode, the hosts sit down with Dr. Prashant Kapoor to review the highest-impact multiple myeloma and AL amyloidosis data from the 2026 ASCO and EHA annual meetings. The discussion centers on the rapidly shifting relapsed/refractory myeloma landscape, where a wave of phase 3 trials of T-cell engaging immunotherapies (bispecific antibodies and CAR T) have now each demonstrated superiority over traditional triplet regimens. Topics Covered1. MajesTEC-3Phase 3, open-label trial of teclistamab + daratumumab SC (n=291) vs. investigator's choice of DPd or DVd (n=296) in 587 patients with relapsed/refractory myeloma and 1–3 prior lines; prior BCMA-directed therapy and anti-CD38-refractory disease were exclusions (only 5% CD38-exposed, none were refractory). Initially presented at ASH 2025, with cytogenetic subgroup data updated at EHA 2026.Key results (34.5-month median follow-up):Median PFS not reached with Tec-Dara vs. 18.1 months with DPd/DVd; 36-month PFS 83.4% vs. 29.7% (HR 0.17)36-month OS 83.3% vs. 65.0% (HR 0.46)Severe infection rate front-loaded: ~35% → ~17% between the first and second 6-month windows, plateauing at ~10–11%/window beyond 12 months; overall grade 3–4 infection 54%, 4.6% fatal infections (mostly without IVIG prophylaxis)EHA 2026 cytogenetic subgroup: 2-year PFS 90% (0 HRCA), 82% (1 HRCA), 76% (≥2 HRCA) — vs. only 14% with DPd/DVd in patients with ≥2 HRCADiscussion points: Applicability to patients at 1st/2nd relapse seen in clinic today; whether infection risk limits use of Tec-Dara at first relapse; implications of the high-risk cytogenetic subgroup data.2. MajesTEC-9Phase 3 trial of teclistamab monotherapy vs. investigator's choice of PVd or Kd in relapsed/refractory myeloma enrolling a heavily anti-CD38-refractory population (100% CD38-exposed, 85% refractory) — the population MajesTEC-3 excluded. Natural comparator: CARTITUDE-4 (phase 3, cilta-cel vs. DPd/PVd in Len-refractory myeloma, 1–3 prior lines, ~25% CD38-refractory/exposed).Key results (~18-month median follow-up):18-month PFS 70% vs. 27% (HR 0.29); 18-month OS 79% vs. 69% (HR 0.6), despite ~2/3 of control-arm patients receiving BsAb/CAR T as subsequent therapyDiscussion points: Cross-trial comparison with CARTITUDE-4 — comparable 18-month PFS on cross-trial comparison, but differing populations (CARTITUDE-4 required Len-refractory disease; MajesTEC-9 enrolled a more CD38-refractory population) and differing maturity (~3-year vs. ~1.5-year follow-up); how Dr. Kapoor chooses between teclistamab and cilta-cel at earlier-line relapse in Len- and CD38-refractory patients, given the divergent toxicity profiles — ongoing infection risk with continuous BsAb dosing vs. the one-time cilta-cel infusion with its rare but potentially irreversible delayed neurotoxicity, IEC-enterocolitis, and CTTLN risk.3. MonumenTAL-3Phase 3 trial — the first phase 3 study of a GPRC5D-targeted bispecific — randomizing 864 patients with relapsed/refractory myeloma (mostly Len-refractory, ~10% CD38-exposed but none refractory) 1:1:1 to Tal-Dara-Pom (n=287), Tal-Dara (n=287), or DPd (n=290), each Talq arm compared against the common DPd control. Presented by Peter Voorhees at EHA 2026 and simultaneously published in NEJM.Key results (24.6-month median follow-up):Both Talq arms significantly improved PFS over DPd: Tal-DP HR 0.28, Tal-D HR 0.33 (both P

Joe thinks that if you're a guy and you go grocery shopping - you shouldn't be pushing the cart See omnystudio.com/listener for privacy information.

O advogado Adriano Soares da Costa detalha por que o parecer do procurador-geral Paulo Gonet pela nulidade da investigação é contraditório, já que o próprio Gonet também foi citado nas mensagens de Daniel Vorcaro.A entrevista revela ainda que Alexandre de Moraes editou pessoalmente o contrato milionário entre o Banco Master e o escritório de sua esposa, além de detalhes sobre o cartão de crédito dado aos filhos e a possibilidade de Vorcaro ter cogitado fugir do país.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.    Transmissão ao vivo de segunda a sexta-feira às 12h no nosso canal do Youtube.  https://www.youtube.com/@OAntagonista  Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:  https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Inscreva-se no canal, ative as notificações e deixe sua opinião nos comentários!  Leia mais em www.oantagonista.com.br | www.crusoe.com.br  #Spotify #ApplePodcasts #AmazonMusic #TuneInRádio #PolíticaBrasileira #BastidoresDoPoder #economia #jornalismo #noticias #politica #Vorcaro #AlexandreDeMoraes #STF #PoliciaFederal #Investigacao #NoticiasBrasil #PoliticaBrasil #Politica #Escandalo #Atualidades

A.M. Edition for Sept. 1. Apple has a new CEO in the form of John Ternus. WSJ reporter Rolfe Winkler explains how Ternus not only has to follow iconic leader Tim Cook, but also come up with an industry-winning plan for AI. Plus, the SEC asks whether firms promising pre-IPO shares in hot companies actually hold those positions. And President Trump backs the film and TV industry in the hopes that a federal tax credit can save Hollywood. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. The AI Therapist: A WSJ Podcast Series Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, Bryan breaks down President Trump calling voters who oppose AI data centers "backwards and poor," a comment landing as Republican candidates nationwide run ads against his own administration's AI buildout. Bryan covers a House Intelligence Committee warning that America's blind spot on runaway AI mirrors the failures that led to 9/11, a growing rift among Democratic Socialists over how openly to embrace communism, and a new California bill recognizing two Islamic holidays in public schools with no equivalent treatment for Christian holy days. He also breaks down revelations that Pentagon-linked influencers spread undisclosed government messaging online. Plus, Bryan covers a new Pentagon strategy of "mowing the grass" to repeatedly degrade Iran's rebuilt coastal defenses, intelligence that the IRGC plotted to kill Netanyahu's son in Miami, a fresh purge of Chinese military generals raising questions about Xi's grip on power, and a promising new CAR-T cell therapy trial for glioblastoma brain cancer. "And you shall know the truth, and the truth shall make you free." - John 8:32   Keywords: Wright Report, Bryan Dean Wright, AI data centers, Trump, GOP midterms, House Intelligence Committee, 9/11, DSA, Democratic Socialists, California, Islamic holidays, Pentagon influencers, Iran, mowing the grass, IRGC, Netanyahu, Miami, China, Xi Jinping, military purge, glioblastoma, CAR-T therapy

Shark Farmer Podcast — Chandler Janes In this episode of Shark Farmer, Rob talks with Chandler Janes of Urbana, Illinois about life, farming, faith, and the path that shaped her career in agriculture. Chandler shares how growing up in central Illinois, losing her dad unexpectedly at a young age, and finding her place on the family farm influenced both her personal life and professional journey.They kick things off with a lively conversation about Beck's Hybrids' big event and the energy of ag shows, including how farmers and ag professionals tend to bring a more positive attitude than the average trade show crowd. Chandler, who works on the digital marketing team at Beck's, talks about the trust farmers place in seed decisions and how the rewards program has helped build long-term confidence on her farm.From there, the conversation turns more personal. Chandler opens up about studying agriculture leadership education at the University of Illinois, then earning a master's degree in agriculture production after her father passed away unexpectedly when she was 20. She talks honestly about grief, faith, and how the loss pushed her to stay close to home, support the family farm, and build a life in Champaign-Urbana.The episode also explores: Chandler's role in agriculture marketing and social media Her experience working for an ag agency and Precision Planting A memorable trip to Germany through an agriculture policy program How she and her husband Connor learned to farm together The realities of raising a young child while balancing work and farm life Why authenticity matters more than polish in interviews and leadership Chandler's perspective is grounded, thoughtful, and refreshingly honest. She talks about resilience not as a buzzword, but as something shaped by real life — tragedy, responsibility, family, and choosing to keep moving forward. Key Takeaways Farm shows and ag events can create a uniquely positive, community-driven atmosphere. Loss and adversity can reshape career direction and personal purpose. Authenticity builds stronger connection than a polished persona. Expanding your network and job shadowing are powerful ways to enter agriculture careers. Family, faith, and adaptability are central to Chandler's life and work. Memorable Themes Resilience after loss Faith in difficult seasons Family farming and shared responsibility Agriculture careers for young women Marketing, communication, and leadership in ag Guest Bio Chandler Janes is an agriculture marketing professional from Urbana, Illinois, with experience in social media, paid media, dealership marketing, and ag communications. She works for Beck's Hybrids and remains closely involved in her family farm while balancing work, motherhood, and community life.

Today on PODCAST with SHEILA, I speak with Drew Ann Long — inventor, mum, and visionary behind Caroline's Cart, the patented, special-needs shopping cart now in thousands of stores across the U.S. and beyond. Drew Ann's journey is one of grit, curiosity, faith, and radical empathy: from sketching her first idea on a dinner napkin to navigating patents, engineering, retail buy-in, and scaling a movement for inclusive design.In this episode, you'll hear:How a mother's frustration became a globally used inventionThe mindset tools and persistence needed to push past “no”Real stories of impact from families who've regained dignity and choiceThe birth of Caroline's Cause, offering scholarships to siblings of special-needs childrenAdvice for anyone who feels underqualified but compelled to create real changeWhat's next for Drew Ann and how she sees the future of inclusive innovationTune in for a deeply human conversation about turning limits into breakthroughs, dreaming big while staying grounded, and designing for empathy.“You don't know what you don't know — and that's okay. Let your purpose lead you into the unknown.” — Drew Ann LongGuest & LinksGuest: Drew Ann LongWebsite / Bio: drewannspeaks.com Caroline's Cause (scholarship program): carolinescause.com Media / news coverage: Caroline's Cart in Target, Lowe's, Kroger, etc. Drew Ann Speakscarolinescause.comidrpp.usu.edu +1#InclusionByDesign • #Innovation • #Accessibility • #Inspiration • #Mompreneur • #DesignForGood • #CarolinesCart • #SpecialNeeds • #Empowerment • #PodcastEpisodeAlso consider: #DisabilityAdvocacy #UniversalDesign #SocialImpact #InventorJourney

September is Blood Cancer Awareness Month, and to mark it, we have a special Director's Cut episode of Managed Care Cast. My name is Maggie Shaw, lead editor at AJMC, and my guest today is Surbhi Sidana, MD, associate professor of medicine at Stanford University, where she leads the Myeloma Disease Focused Group and serves as associate director for clinical research in the BMT and Cell Therapy Division. We talk about her path into myeloma research, the field's shift from a once-fatal diagnosis to real conversations about cure, the barriers patients face accessing CAR T-cell therapy, and her advice for the next generation of hematologists.

Retail veteran Peter Chapman has spent 20 years teaching brands what buyers actually want to hear — and it's rarely another pitch about how great your product is. After 19 years at Loblaw running fresh merchandising across Atlantic Canada, Peter went out on his own in 2008 to help suppliers build real relationships with retailers. On this episode he sits down with Phil and Kenny to unpack what separates the brands that get on shelf from the ones that get shown the door. The conversation digs into why "walking the store" is a non-negotiable part of the job, how store staff are the industry's most underused source of intel, and why understanding a retailer's economics beats fighting them. Peter also shares why frozen and refrigerated have quietly become the categories to watch, and how a wave of Canadian-first sentiment is reshaping what brands should be leading with — at home and in export markets. Find Peter at SKUfood.com, where he's published a weekly industry newsletter for 347 straight Fridays, and connect with him on LinkedIn. In this episode: From a 1983 grocery job to 19 years at Loblaw to going solo in 2008 Why buyers want a plan, not a "look what I've got" pitch Walking the whole store (not your own set) to find where you really fit Store staff and cashiers as underrated sources of real-world sales insight The shift toward frozen, refrigerated, and Canadian-made products

Kat ditched the show for a hike, so Big Rich, TD and Fletch are left unsupervised and tackling one of society's biggest moral dilemmas: Do you clean your table at a fast-food restaurant, and are you a terrible person if you don't return your grocery cart? Spoiler alert: TD is proudly Team Leave-the-Cart. Plus, Rich has a few tricks to help you save some cash this weekend.See omnystudio.com/listener for privacy information.

BUFFALO, NY – August 31, 2026 – A new #editorial was published in Volume 17 of Oncotarget on June 8, 2026, titled “Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives.” The editorial was led by first and corresponding author Bhartendra Sharma from Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India, along with co-authors Sukhbir Kaur, Vikas Sharma and Sanjay Soni. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy that uses immune cells naturally present within tumors to attack cancer. Unlike chimeric antigen receptor (CAR) T-cell therapy, which genetically modifies a patient's T cells to recognize specific tumor antigens and has achieved its greatest success in hematological malignancies, TIL therapy has shown potential in several types of solid tumors. The approach has a history spanning more than four decades. Steven Rosenberg first isolated TILs from a mouse tumor in 1982, and subsequent experiments demonstrated antitumor effects when TILs were combined with cyclophosphamide and interleukin-2 (IL-2). In 1988, Rosenberg and colleagues reported favorable clinical outcomes after administering TIL therapy to patients with metastatic melanoma. Full press release - https://www.oncotarget.com/news/pr/tumor-infiltrating-lymphocyte-therapy-offers-a-promising-approach-for-treating-solid-tumors/ DOI - https://doi.org/10.18632/oncotarget.28883 Correspondence to - Bhartendra Sharma - bhartendrasharma@mgumst.org Intro video - https://www.youtube.com/watch?v=QAr_R4WCJfk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28883 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, tumor infiltrating lymphocytes, solid tumors, adoptive cellular therapy, immunotherapy To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

En este Smollop de El Dollop, conocemos la increíble historia de Frank “Woody” Woodbine, un empresario, cartógrafo y promotor de caminos que comenzó ayudando a automovilistas varados y terminó contribuyendo al desarrollo de la señalización de carreteras en Estados Unidos. También acompañó a la famosa “Chica del Trigo de Kansas” en una gira nacional, codeándose con políticos y funcionarios… hasta que algo comenzó a romperse. Una historia que empieza como “este señor era bastante útil para la sociedad” y termina en “¿por qué está vestido así y por qué le gustan tanto los pollos?” Síguenos y visita nuestro sitio oficial: https://www.instagram.com/eldollop https://twitter.com/eldollop https://www.facebook.com/eldolloppodcast Los Dollops: @ninguneduardo @bryanthemachine http://eldollop.com Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be 15 million (4.6% US population); 34% have 2+ AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://buff.ly/fYgRfZ0 POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0 MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG British Dermatology Biologics registry (BADBIR) 18976 #PSO pts had incidence serious infxns (SIE) 28 SEI/1000 Pt-Yrs; higher if they had prior infxn (79/1000 PYs). SIE signif lower w/ RIZankizumab (HR 0.74-.80) vs BROAD, ETN, other standards Rxs. SIE deaths rare (1.81/1000 PYs) https://t.co/GTr3DLCVXs 39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower mortality jSSc (7.7% vs. 20.4%) https://t.co/vflarmwSyv Italian SPRING cohort of #SSc pts found only 5.3% (of 1689 pts) without the typical scleroderma pattern on nailfold change by NVC. They had milder dz, with less vascular dz (pitting scars 33 vs 48%), telangiectasias (52 vs 74%), calcinosis 3.4 vs 12%) & higher DLCOs at 12, 24, https://t.co/AoNAhVYfII Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ 3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo

We love to hear from our listeners. Send us a message.On episode 136 of Cell & Gene: The Podcast, Host Erin Harris welcomes back Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath to discuss why autoimmune CAR T is moving rapidly from an emerging concept toward a potentially transformative treatment approach. They talk about the very different benefit-risk calculus in autoimmune disease compared with oncology, the patient and caregiver burden of conditioning, apheresis and long-term monitoring, and the need to rethink clinical trial endpoints around meaningful outcomes. They explore the potential of in vivo CAR T and circular RNA to eliminate some of the biggest barriers in the current treatment pathway, while discussing the scientific and durability questions that remain.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

In this week's episode, Blood editor Laurie Sehn interviews Drs. Efstathios Kastritis and Lucia Chen on their latest articles published in Blood. Dr. Kastritis shares insights and results from the final survival analysis of the ANDROMEDA trial, which determined that adding daratumumab to cyclophosphamide, bortezomib, and dexamethasone improves hematologic responses and overall survival in newly diagnosed AL amyloidosis.  Dr. Chen elaborates on the key benefits of Ikaros degradation for reducing T-cell dysfunction in MM patients: Ikaros degradation by mezigdomide enhances anti–B-cell maturation antigen CAR-T and bispecific TCE therapy efficacy in vitro and in vivo. Featured Articles: Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone for Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis | Efstathios KastritisIkaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies | Lucia Chen

Andrew Vontz has been an endurance athlete for 38 years. In March doctors found a tumor running from his the cavity between his lungs up across his neck that had displaced his carotid artery and was crushing his trachea. — This is the cancer episode. Andrew is five months into treatment for diffuse large B-cell lymphoma. He has been through six rounds of chemo, a cytokine release storm, multiple hospitalizations, and in September will go to Dana Farber Cancer Institute for three weeks to get CAR T genetic therapy. He talks about how he discovered he had cancer, living with uncertainty, going through chemo, what thirty-eight years of endurance sport did and did not prepare him for, and how listening to his body has guided his cancer experience. — Guiding the conversation is the titan of entrepreneurship, leadership development, and finance Shannon Jones, who teaches Entrepreneurship Through Acquisition at the University of Colorado Boulder's Leeds School of Business, writes the TranscendenCEO newsletter, and was a two-sport Division I athlete. Shannon joined Andrew on a previous episode to talk about building and winding down The Better Lab. — Thank you to everyone in this community who has reached out to provide positivity, prayers, encouragement, and support during this experience. — Recorded August 21, 2026, three days after Andrew's sixth round of chemo. — The media landscape has changed. Scripted is out. Real is in. Being a great podcast guest or host and being able to operate in dynamic unscripted contexts isn't optional. It's now a mandatory skill for senior leaders and doing it well isn't easy. That's why Andrew Vontz started __https://www.onerealvoice.com/__ to help industry leaders thrive on podcasts, panels and the internal and external high-stakes open-ended conversations where reputations are built and business is won. — When you're ready to be great, DM __https://www.instagram.com/hardwaypod__ or reach out to hello@onerealvoice.com. — To support this work, become a paid subscriber to the Choose the Hard Way Substack at __https://alwaysthehardway.substack.com__. — With over $1 trillion in transactions to date, Blockchain.com is your trusted partner on your crypto journey. Go to Blockchain.com to get started today no experience required. — Lauf is the Apple of bike design and they make elegant products that just work better than everything else. Check them out at __https://www.laufcycles.com__. — Thank you to Sunlighten infrared saunas for helping make it possible for my family to have an mPulse sauna. Being able to relax and recover in our mPulse sauna when possible between treatments is healing and feels like a luxury. I'm grateful for your support. Sunlighten: __https://www.sunlighten.com/__ — Thank you to Peloton of "come on Peloton, you got this" fame for following my cancer experience and surprising me with a Peloton Tread. Being able to go to the garage and move is huge for me, and Molly, especially on days when I'm too wiped to be able to take the dogs out. It's a next level treadmill and it takes me places. Peloton: __https://www.onepeloton.com/__ — Andrew Vontz's Choose the Hard Way newsletter: __https://alwaysthehardway.substack.com/__ — One Real Voice: __https://www.onerealvoice.com/__ — Instagram: __https://www.instagram.com/hardwaypod__ — LinkedIn: __https://www.linkedin.com/in/andrewvontz/__ — Shannon Jones's TranscendenCEO newsletter: __https://transcendenceo.substack.com/__ — Follow Shannon Jones on LinkedIn: __https://www.linkedin.com/in/wshannonjones/__ -  

En cette journée mondiale du chien, on va rentrer dans les coulisses de la pâtée. Bon, déjà, point de départ : c'est un énorme business. Pas loin de 3 milliards d'euros pour nourrir nos chiens en France. Et quand il y a un énorme business, ça suscite les convoitises des marques pour tenter de nous vendre toujours plus. Et ça tombe bien, parce qu'on est gaga de nos animaux de compagnie... Ecoutez Olivier Dauvers : les secrets de la conso du 26 août 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

The regular 9 to 5 didn't work for two busy hockey moms, so they teamed up to share their love of charcuterie. KMOX's Megan Lynch catches up with Marissa Mainer and Julia Lohmeyer of Platter & Pine traveling charcuterie cart.

Drs. Ghia and Scarfò discuss how CAR T-cell therapy is emerging as a powerful option for high-risk CLL and Richter transformation, especially in patients who have failed BTK and BCL-2 inhibitors. They stress that achieving deep remissions, choosing the right patients, and referring early to specialized centers are critical to improving outcomes.

¡¡NUEVO PODCAST!!-Cuauhtli Arau…  “Pensar en orden para pensar mejor”  -Gianco Abundiz…  “Compras en línea”  -Doctor Federico Sandoval García… “Desgaste de Cartílago”  -Químico, Luis Manuel Guerra… “Semana Mundial del Agua”  -Arriba Corazones... Rafael Perrín.    

This month, the gals welcome Bridget Todd, author and host of There Are No Girls On the Internet, to discuss a doped-up dog, a most unwelcome hospital visitor, the worst best friend, sneeze-farts, beginner porn, an update from the Methodists, and yet another victim of Hobby Lobby. Tune in now for Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

Tight seeding windows and wet spring conditions routinely test broad-acre producers across the Canadian Prairies, making field efficiency and tendering speed critical to getting a crop in the ground. To cover more acres with fewer stops, equipment manufacturers are expanding cart capacities and redesigning handling systems to keep drills moving during narrow planting windows. At... Read More

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Joshua Hill and Jeffery Weitz on their latest articles published in Blood. Dr. Hill and Dr. Michaelis discuss the evolving landscape of infection risk in adults receiving bispecific antibody therapies for advanced B‑cell malignancies. They explore how these risks differ from those seen with allogeneic transplant, CAR T‑cell therapy, and traditional CD20‑directed antibodies, and touch on emerging approaches such as trispecific antibodies and evolving strategies for supportive care, including immunoglobulin replacement. In the second half of the episode, Dr. Michaelis is joined by Dr. Jeffrey Weitz to discuss new insights into the role of histidine‑rich glycoprotein in hemostasis. Their conversation delves into HRG's interactions with key platelet receptors, its behavior in inflammatory states like sepsis and COVID‑19, and how these observations may reshape thinking about thrombosis risk and future therapeutic approaches.Featured Articles: How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies | Joshua Hill, MDHistidine-rich glycoprotein modulates platelet adhesion and aggregation by binding to GPIbα and GPIIb/IIIa | Jeffery Weitz, MD

We Like Shooting We Like Shooting - Ep 676 August 17, 2026 Presented by This episode of We Like Shooting is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Gideon Optics (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Night Fision (Code: WLSISLIFE) Otis Technology (Code: WELIKESHOOTING15) Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   Gear Chat Note Montana Knife Company stoned goat ultrahttps://www.montanaknifecompany.com/products/stoned-goat-ultra EAA Corp. Girsan Witness2311 CMX XXX Discover the Witness2311 CMX XXX, a compact double stack 1911 with 16+1 capacity, a slim grip, firing pin block safety, and two-tone finish. The Girsan Witness2311 CMX XXX is a compact single-action 9mm pistol from EAA Corp. with 16+1 capacity using Check-Mate magazines. It features an RMSc-footprint optic-ready slide, 3.4-inch coned barrel, two-tone Cerakote finish, low-profile 3-dot sights, ambidextrous thumb safety, 4-slot Picatinny rail, and EAA limited lifetime warranty. Availability: Available for purchase via Add to Cart on eaacorp.com (no explicit stock, release date or additional retailers stated) Cost: $899 Special: Streamlined compact grip with aggressive texturing, low-profile magwell, and automatic firing pin block safety replacing traditional grip safety for 16+1 capacity without added bulk Odysee (Nick) SecondWatch FTN.6 Suppressor Pack Update: We received overwhelming feedback that people did not like the text. The intention was to save on what needed to be engraved. Since it is so unpopular, all text has been removed from the model… The FTN.6 Suppressor Pack is a downloadable set of 3D-printable files for DIY suppressors released by SecondWatch on August 15, 2026, via Odysee. It includes updated designs for rimfire, 5.56, and 300 BLK models that are described as the quietest FTN variants to date, matching or surpassing many commercial suppressors in head-to-head testing. The pack continues the FTN (Fuck The NFA) series focused on accessible, low-cost polymer printed silencers. Availability: Released August 15, 2026 on Odysee (@SecondWatch); downloadable files Special: FTN.6 Air is a very lightweight (~10.6 oz) and slim rifle suppressor using thread adapters; modular flash hider and compensator add-ons; FTN.6 Rimfire offers similar sound reduction to FTN.5 but in a smaller package Defiance Machine (Nick) Defiance Machine Deviant Comp Rifle Action Deviant COMP – The new standard for PRS competitors. The Deviant COMP refines our popular Deviant model into a purpose-built precision rifle action designed specifically for PRS competitors who demand speed, consistency, and reliability under pressure. Built with the features competitive shooters actually want, the Deviant COMP features an oversized bolt for fast cycling, an AW magazine cut compatible with both AW and AICS magazines, and guaranteed headspace for repeatable accuracy and hassle-free builds. This makes the Deviant COMP a competition-ready package that is ideal for PRS. Finished with nitride included at no additional cost, the Deviant COMP delivers premium performance at an exceptional value. Specifications Integral scope mount/rail. Integral recoil lug. Defiance swept legacy bolt design. Oversized competition bolt knob. Smooth chrome-moly bolt action with anti-bind design. Recessed bolt lugs, Mini-16 extractor, and plunger ejector. AW magazine cut. Trigger pins included. Nitride finish included. Why choose the Deviant COMP? PRS competition-ready feature set. Integral rail and recoil lug means more rigidity and reliability when it matters most. Receiver is made from once piece of pre-hardened aircraft-certified 416 stainless steel, allowing for tight manufacturing tolerances and increased performance. One-piece legacy bolt, machined to exacting tolerances required to cycle as smooth as possible. Swept bolt handle design to allow plenty of clearance with your rifle scope. Precision extraction system that significantly increases initial extraction and improves smooth bolt cycling. Need an extra bolt? Extra bolts are available when purchasing your action over the phone with our team for $495 each (includes extractor, ejector, and fire control assembly). The Deviant Comp is a purpose-built short-action bolt-action receiver from Defiance Machine, refined from the standard Deviant for PRS competitors. It is machined from a single piece of pre-hardened 416 stainless steel with an integral scope rail and recoil lug for rigidity and guaranteed headspace. It features an oversized competition bolt knob, swept bolt handle, anti-bind design, AW/AICS magazine compatibility, nitride finish, and a smooth chrome-moly bolt with recessed lugs, Mini-16 extractor, and plunger ejector. Availability: Available through retailers including Red Hawk Rifles (add-to-cart with options) and Altus Shooting (currently out of stock for specific variants like RH/308) Cost: $1,495.00 Special: PRS-optimized with oversized bolt for fast cycling, AW magazine cut compatible with AW and AICS, integral rail/lug for rigidity, and included nitride finish at no extra cost 270 Videos Removed from YouTube for FRN and WLS in Recent Days 270 videos removed from youtube for FRN and WLS in the last several days. Supplementary Research: Firearms Radio Network (FRN) produces multiple gun-related podcasts including the long-running We Like Shooting (WLS) show, which features discussions on firearms, gear, training, and current events. The claim states that 270 videos associated with these channels were removed from YouTube over several days in 2026. YouTube's enforcement actions in 2026 have included widespread removals tied to updated policies on AI-generated content, community guidelines, and monetization standards, with millions of videos and channels affected platform-wide. Gun Fights Play the best Price Is Right-style GunBroker game on the internet. Gun Fights Live DisplayFollow the game, prices, and reveals as they happen.Open the live display BangRank A live cast ranking segment for anything and everything in the gun world, powered by questionable certainty, strong opinions, and audience voting. BangRank Live VotingScan or open the link to rank along with the show.https://welikeshooting.com/rank   WLS is Lifestyle GunCAD Index 2011 OPTICS MAXXING by Foaps Files Designed specifically for the Nightalliance 2011 Maxxing frames. There are two styles to choose from and six different optic mounting patterns. Each … This is a 3D model release on GunCAD Index containing STEP and STL files for optic mounts designed specifically for Nightalliance 2011 Maxxing frames. It offers two styles, six optic mounting patterns (including ACRO, Docter-Noblex, Pic Rail, RMR, RMSc, T1-T2), Gas Pedal and Non-Gas Pedal variants, plus length options for Full, Commander, and Short frames. The page serves as an indexed preview only; actual files must be acquired from the original source. Why it Matters: Enables precise red-dot integration on custom 2011 pistols in the growing 3D2A community, allowing shooters to upgrade iron-sight platforms with modern optics without factory limitations. The Vibe: Clean, modular CAD aesthetic with purposeful engineering details—gas pedal extensions, multi-pattern plates, and frame-specific lengths that emphasize performance-oriented customization over factory aesthetics. Hot Take: In the 2011 maxxing scene, bolting a quality optic directly to a printed or custom frame is now the baseline, not an afterthought. GunCAD Index Freedomware Sedco SP22:8 SPEDBRO SP22 Printable 22LR Pistol Don't like the standard Jennings J22? Well here's his neglected brother, the Sedco SP22. A knockoff of the already trash J22. NOT FOR DISTRIBUTION O… The SPEDBRO SP22 is a 3D-printable knockoff of the Sedco SP22 / Jennings J22 design by FreedomWare. It is a rimfire 22 Long Rifle handgun classified as a printed firearm using DIY barrel, bolt, and fire control with no firearm parts required. The release includes multiple STL files, reference images, a drill key, and README; total size 2.5 MiB; explicitly not for distribution on DEFCAD; tagged for FOSSCAD and 3D2A. Why it Matters: Provides a fully printable 22LR plinking handgun design that requires no commercial firearm parts, enabling DIY production of a simple rimfire pistol using consumer 3D printing and basic tools. The Vibe: Utilitarian homemade aesthetic with blocky printed polymer grips and frame, exposed metal DIY barrel/bolt, and reference photos showing side-by-side comparison to a Bryco 22; raw FOSSCAD open-source vibe with technical STL and drill-key files. Hot Take: A knockoff of the already trash J22 – the neglected brother Sedco SP22 now lives on as a fully printable FreedomWare project for the 3D2A community. Guncadindex Tritschi 60 Seconds Timer for Shooting Range A self-built horizontal hourglass-style mechanical countdown timer using a stepper motor, GT2 belt, Nema17, Arduino Nano, and 3D-printed parts. It provides a large 160 cm x 90 mm visual window that transitions from white to red over exactly 60 seconds for timing K20-K23 handgun events in DSU disciplines, with startup red LED/beeper sequence, green LED indicator, optional beeper, and planned light-sensor start. Powered by 3S Li-Ion with BMS; designed in TinkerCad and printed on Prusa MK4/Sovol SV08. Why it Matters: Best Use Case: Competition (K20-K23 handgun events in German DSU shooting sports; helps pace 18 shots in 60 seconds without digital distractions or crowd noise) Hot Take: Quick Pro/Con: Pro – Large peripheral-vision mechanical analog display improves focus and timing accuracy; Con – Self-built (requires 3D printing,...

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

Charles Spurgeon's beloved “John Ploughman” returns – plain-spoken, sharp-witted, and full of gospel truth. Following the tremendous response to John Ploughman's Talk, Spurgeon offers this second volume of plain counsel for everyday people. With colorful illustrations drawn from rural life and seasoned with humor, he speaks straight to the heart – warning against folly, exposing hypocrisy, encouraging honest labor, and encouraging all to turn to Christ. Written “in the simplest form of our mother tongue,” John Ploughman's Pictures uses pointed proverbs and everyday situations to make biblical wisdom stick. Whether rebuking drunkenness, urging integrity, or lifting hope for the prodigal, Spurgeon is ever the master with words. Both warm and bold, humorous and deeply serious, this classic reminds us that the gospel is for ordinary people and for daily living – and that plain truth is often the best kind. About the Author Charles Haddon (C. H.) Spurgeon (1834-1892) was a British Baptist preacher. He started preaching at age 16 and quickly became famous. He is still known as the “Prince of Preachers” and frequently had more than 10,000 people present to hear him preach at the Metropolitan Tabernacle in London. His sermons were printed in newspapers, translated into many languages, and published in many books.

See omnystudio.com/listener for privacy information.

Catching up with the Chat/Discord! The great Louisville debate! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Moving Medicine Forward, Jeremy Schrand is joined by Luke Devey, Chief Medical Officer at Quell Therapeutics, and Savannah Doliboa, Chief Commercial Officer at CTI, to discuss how engineered regulatory T cell therapies are being developed to “chill, not kill” the immune system. The conversation explores Quell Therapeutics' approach to Treg cell therapy, the complexity of launching advanced cell therapy trials across Europe, and how strong collaboration helped accelerate study startup for patients with serious autoimmune diseases.00:00 Introduction to Quell Therapeutics and its "Chill, Not Kill" approach to engineered Treg cell therapies 01:13 What engineered regulatory T cells are and how they differ from traditional CAR-T therapies 02:31 Launching a first-in-human basket trial in rheumatoid arthritis and systemic sclerosis with CTI03:05 Why Quell selected the UK, Germany, and Spain for study startup and site activation05:27 Finding the right CRO partner: Why Quell chose CTI Clinical Trial and Consulting Services 07:21 Navigating regulatory pathways, site readiness, and operational complexity in advanced cell therapy trials 10:47 The strategy behind accelerating study startup and overcoming traditional delays12:05 Achieving first-patient-ready status in 113 days, cutting benchmark timelines by 48%13:57 The patient impact: addressing significant unmet needs in rheumatoid arthritis and systemic sclerosis17:00 Key lessons from the trial and building a culture focused on collaboration, innovation, and patient outcomes 20:58 What's next for Quell Therapeutics and the future of engineered Treg cell therapies

EXCLUSIVE: Trump Sparks 'Sitting Duck' Assassination Fears With Catering Cart 'Farce'Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Jason had a photo day and he's feeling good! Jason and Colleen share their nighttime skin care routines -- think face tape! JUST SAYIN': Colleen's plea to Costco -- people need shopping cart driver's ed! And we take a gander at Arby's new fall menu. UV umbrellas are trendy and will keep you safe from the sun! Bob Iger buys the Los Angeles Lakers and we speculate about what sports team we can buy (and afford...) and FIX MY LIFE: Lizzie's toilet troubles!SCREEN QUEENS: Holly stumbled into "Batman: Caped Crusader" on Amazon Prime, Jason is infuriated about "Double Lives of Suburban Wives" for a VERY specific reason, and Colleen completed her assignment by watching the first episode of "Dexter." Martha Stewart is gorgeous and serving looks! And remember that time that we almost got blown away at the Minnesota State Fair? Plus, Reader's Digest's list of things to do if you have a UFO sighting!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Valerie Abraham as she shares how her upbringing in France, life in America, and marriage to her Egyptian American husband have shaped her unique approach to cooking and hospitality. From Sunday morning coffee and pastries to practical table décor on a budget (including dollar store dishes!), Valerie offers inspiring ideas, kitchen must-haves she uses daily, three favorite book recommendations, and a flavorful menu influenced by multiple cultures. She also reminds us that hospitality is an imitation of God, the ultimate giver of every good gift. We close with a moving, thought-provoking conversation about both giving and receiving hospitality during a season of grief. We're so glad you're here! Visit www.comeoverfordinner.com for recipes, product links, and more!

In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.

Wednesday, August 12, 2026 Today, Trump doesn't rule out using emergency executive power to interfere with the midterm elections; the transparency president has expanded the definition of executive privilege so his private advisors can't be questioned by Congress; the White House is asking the Justice Department to consider new Reflecting Pool charges; Trump was stuffed into a catering cart and spirited to a secret plane after he ditched the Qatari Air Force One in Turkey; weeks after Belgium's diamond industry gave Trump a ring with 321 diamonds, 56 sapphires, 13 emeralds and six rubies, it was exempted from paying a U.S. tariff; Judge Talwani has expanded her block on the Postal Service tampering with mail ballots; the government has awarded a $150M contract for migrant children's lawyers to a Trump-linked Texas law firm; plus Allison and Dana deliver your Good News. Thank You, HoneyLove Save 20% Off Honeylove by going to honeylove.com/DAILYBEANS #honeylovepod  #sponsored Thank You WildGrain Get $30 off your first box + free Croissants in every box. Go to Wildgrain.com/DAILYBEANS to start your subscription.  The Trump Epstein Memorial Bookmobile The Daily Beans is proud to partner with Miles Taylor and our friends at DEFIANCE.org For a limited time, members of the Daily Beans community can receive a FREE 3-month full membership to DEFIANCE.org and gain access to one of the fastest-growing pro-democracy movements in America. Join here: https://www.defiance.org/beans Diamond Dames - Subscribe here: https://youtube.com/playlist?list=PLdw5wpZniLeg&si=YB1KlvnjmA4CxxV3https://diamond-dames.simplecast.com/ The Latest Breakdown→ NEW: Judge Orders Todd Blanche to Explain Epstein Redactions in Open Court StoriesDemocrats want answers about 18-karat gold ring given to Trump | MS NOW Trump Said to Have Secretly Used Military Jet to Leave Turkey Amid Threats From Iran | The New York Times White House Asks Justice Department to Consider New Reflecting-Pool Prosecution | WSJ Trump executive privilege memo could hamper Democrats if they win Congress | CNN Politics Trump signals openness to unconstitutional plot to take over elections | Democracy Docket A judge expands a block on U.S. Postal Service work on Trump's mail-in voting order | NPR Trump administration awards $150M migrant child contract to Texas firm | AP News Good Trouble Friday August 28 in DCMarch On Washington 2026 -marchonwashington2026.com March on Washington: Defend the Vote - Mobilize Check your voter registration and deadlines → Voter Registration Deadlines - Vote.org →Blue Wave California- secure.actblue.com/donate/msw-bwc →Helpline Orientation- Spanish Speakers Needed! · VoteRiders →Help save Texas from Ken Paxton! →NO HATE in WA State →Stand With Minnesota →iceout.org Good Newsdana-goldbergs-southwest-funnyfest Oct 9 -Email Dana@DanaGoldberg.com for sponsorship informationTickets for Dana Goldberg: Outrageous - Sep 23 - Den Theater - Chicago  →Share your Good News & Good Trouble - The Daily Beans →Beans Talk audio -beans-talk.simplecast.com Subscribe to the MSW on YouTube - MSW Media - YouTube Our Donation Links The Trevor Project - trevorproject.org/beans Blue Wave California - ActBlue.com/donate/msw-bwc Donate to Public Citizen - https://citizen.org/beans/ Donate to It Gets Better / The Daily Beans Fundraiser Pathways to Citizenship - boomerang - pathways  Dana and The Daily Beans support of Human Rights Campaign ONE CAUSE HRC The Daily Beans supports It Gets BetterNational Security Counselors - Donate, WhistleblowerAid.org/beans Dr. Allison Gill - The Breakdown | Allison Gill, Mueller, She Wrote @muellershewrote.com - Bluesky, MSW & The Daily Beans Podcast @muellershewrote - Instagram, MSW Media - YouTube →Federal workers email AG - fedoath@pm.me Dana Goldberg - Dana is on Patreon! At Dana's Dugout, @dgcomedy - Bluesky, @dgcomedy - IG, Dana Goldberg - Facebook,  DanaGoldberg.com More from MSW Media - Shows, Cleanup On Aisle 45 pod, The Breakdown | Allison Gill Reminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! patreon.com/muellershewrote Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:https://apple.co/3XNx7ckWant to support the show and get it ad-free and early?https://patreon.com/thedailybeanshttps://dailybeans.supercast.com/https://apple.co/3UKzKt0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Double Tap Double Tap - Ep 474 August 10, 2026 Presented by This episode of Double Tap is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Gideon Optics (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   Dear WLS Question from Ben B from Kansas Ben B (TLDR from last week: Bought a Bergara B14-HMR that wouldn't group and had a crooked-looking scope. After replacing the rail, rings, and checking the scope, a gunsmith finally discovered the rifle's mounting holes were drilled at a 45° angle from the factory. The manufacturing defect that made proper alignment impossible.)Continuation of the story from where it cut off last week- We looked in there and about half the threaded hole in the receiver was visible through the rail. Well shit… We tried a different rail and it was the same. I decided to contact Bergara to see if they would fix it. I started a warranty case with them and they sent an RMA form and asked me to ship the rifle to them. I sent it over and assumed that everything would be straightened out. After several weeks with zero updates, I called and asked for some kind of information. I even gave them exact instructions on how to replicate the problem. They said they would update me when they got it into their system and when they got started on the inspections. After they had it for a month they finally shipped it back and their conclusion was that the rifle was in spec. About a million emails later and both sides being stubborn, I gave up. Obviously they weren't going to fix it and I was at my wit's end. I brought it back to the gunsmith and had him drill and re tap the receiver holes to a big enough size to line it up. In spec my ass. Ever since then the Bergara name has left a bad taste in my mouth. I'm not really on social media and don't know how to get through how bad of an experience I had with them because I think people need to know. I am sorry for the long story but I already left a lot of details out. Just remember you asked for this Shawn Question from Bama Chris I know this will take forever And I'm expecting And answer sometime in about 2029 … Just found out the other day from Savage that my current credit card provider that used to be discover card and is now Capital One is a bunch of anti-gun Cucks … I need to cancel My over 20-year account With this credit card company Actually I have two accounts Cancel them both And find a credit card company That is 2a friendly Any suggestions… This is for Customer-Based Credit line Not Business related Processing. Wouldn't man if it was A car that instead of me getting cash back All of that went towards donations Second Amendment Foundation or other Friendly OrganizationsThanks Five squares second call defense is awesome High Point rules and Jeremy is my spirit animal Question from Anonymous Coward from Kentucky Question from Coward with anonymity from Virginia. I know you have probably said it a hundred times, but I have no experience with 3d printing. What is the best starter printer that's user friendly and capable. Great show, thanks! Question from Peter J from WA Peter J from WA, Dear WLS, I'm interested in either buying a factory ported pistol or having one I own custom ported. Is it really worth the hype? Im debating on either getting a CZ ported P10c or getting my CZ P10F ported. Use case would be more for range but would carry the ported p10c since I carry a non ported one currently. I more than with do what Jeremy or Nick tell me what to do. Thanks Question from eTexNerd from Texas Dear wls, from eTexNerdFirst a big Ole howdy from the upper east side of Texas to Tom Bowers! Question: once Bowers group is running production in Texas, won't I be able to buy his suppressors without federal redtape? I think Texas passed a law to allow intrastate transfer of suppressots made within Texas. I'm a little vague on the legal details but figure Tom being in the industry would know more. Maybe the cartoon savage legal hawk can explain this too. VIVA LA TEJAS! WINNER Question from Anonymous Coward from Texas Dear WLS. from Organiv Nut Milk Producer,Last week I learned about a new trend called ballmaxxing. Assuming one wished to take up this hobby, would you recommend switching from appendix carry to SOB? Gun Industry News Inside Safariland Derya Arms Derya MAX Cadre Derya Arms (Jacksonville, FL) has released the Derya MAX, a proprietary magazine-fed 12-gauge semiautomatic shotgun developed over three years with input from champion-level competitive shooters. It uses a self-cleaning curved gas piston that reliably cycles loads from 7/8 oz target shells to 3″ magnums, incorporates a proprietary MAX Brake and double-buffered recoil system to minimize muzzle rise and felt recoil, and ships with a hard case, tool roll, and magazines. The design targets 3-Gun, IPSC, home defense, and training applications with an adjustable adaptive stock, AR-compatible pistol grip, full-length Picatinny rail, flip-up iron sights, and threaded barrel. The Gist: Recently released (no specific date or retailers stated) Impact: $2,499.00 MSRP Bottom Line: 12 ga; 5/10-round magazine capacity; self-cleaning gas piston; 14″, 18″, or 20″ barrel options; 38″ OAL, 9.5 lb; folding iron sights, full Picatinny rail, mobile chokes (Full/Modified/IC), adjustable stock (12-15″ LOP), MAX Brake + double-buffered recoil system, ships with 2 magazines (6 + D-TAK optic in Factory Exclusive version) Theoutdoorwire SK Guns Relaunches Limited Edition Pancho Villa from La Revolucion Series in Stainless Steel SK Guns has relaunched the first pistol in its La Revolucion series as a limited-edition stainless steel Full Size Government Model Colt 1911 chambered in .38 Super. The highly polished revolver-style 1911 features selective 24k gold plating, intricate historical engravings commemorating Pancho Villa and the Mexican Revolution, and custom Antique Pearl Krinite grips with antique gold peso coin medallions. Limited to 300 units, it marks the 100th anniversary of Pancho Villa's passing (1878-1923). The Gist: Relaunched August 7, 2026; limited to 300 units; follow SK Guns on Instagram and Facebook for production launches Bottom Line: Caliber .38 Super; stainless steel frame, slide, barrel and hardware with selective 24k gold plating; engravings include Monument to the Revolution, “División del Norte” banner “Fusílenlo, después averiguamos”, Durango coat of arms, “REVOLUCION”, “El Centauro del Norte”, Pancho Villa portrait “1878-1923 Centenario”, bandolier with .30-30 cartridges, Mexico coat of arms 1899-1947, and Cannas floral scroll with selective shading; Antique Pearl Krinite grips with replica antique gold peso medallions Eaacorp Girsan Witness2311 CMXX The Girsan Witness2311 CMXX from EAA Corp. is a compensated single-action 2011-style pistol offered in 9mm, 10mm, and .45 ACP. It features an integral barrel compensator, 4.25″ bull barrel, lightening-cut slide, RMSc optic-ready footprint, tuned 4.5 lb trigger, auto firing pin block safety (no grip safety), ambidextrous thumb safety, full accessory rail, and improved high-texture grips with a Cerakote black finish. The Gist: Available for purchase now (listed as NEW on EAA Corp. website) Impact: Starting at $1,149 (MSRP) Bottom Line: 9mm (17+1), 10mm (15+1), or .45 ACP (11+1); 4.25″ bull barrel with integral compensator; RMSc optic ready, fiber optic front sight, tuned 4.5 lb trigger, auto firing pin block, ambidextrous thumb safety, full accessory rail, Cerakote black finish, EAA limited lifetime warranty Walkersgameear Walker's Game Ear Boomies Passive Muffs Walker's Game Ear Boomies Passive Muffs are a toddler-specific (ages 1–3) passive hearing protection product with a certified NRR of 23 dB. The slim, lightweight design features soft ear cushions, impact-resistant materials, and a contoured, stay-put fit engineered for active play and small head sizes without requiring batteries or electronic components. The Gist: Currently available for purchase (listed as new product with Add to Cart option) Impact: $29.99 MSRP Bottom Line: Passive NRR 23 dB; lightweight/contoured for toddlers 1–3 years; soft cushions, impact-resistant, stay-put fit for active indoor/outdoor use; no batteries or switches; SKU GWP-YM2-VAR Before we let you go – Join Gun Owners of America We'd love if you supported the show, join Agency 171 at agency171.com. Lot's of prizes, rewards and kick ass swag. No matter how tough your battle is today, we want you here fight with us tomorrow. Don't struggle in silence, you can contact the suicide prevention line by dialing 988 from your phone. Remember – Always prefer Dangerous Freedom over peaceful slavery. We'll see you next time! Nick – @busbuiltsystems | Bus Built Systems Jeremy – @ret_actual | Rivers Edge Tactical Aaron – @machinegun_moses Savage – @savage1r Shawn – @dangerousfreedomyt | @camorado.cam | Camorado

Guest: Dr. Pere Santamaria is a Professor at the Cumming School of Medicine at the University of Calgary and Group Leader at the Barcelona Institute. He discusses how his lab studies the mechanisms underlying autoimmune diseases, with a focus on regulatory T cell biology and antigen-specific immune tolerance. He also explains how his team developed a nanomedicine platform that reprograms autoreactive T cells into regulatory cells, offering a targeted approach to treating autoimmune disorders without suppressing normal immune function, and shares the challenges of translating this technology from the lab to the clinic. Featured Products and Resources: Find the right antibodies for your research and start integrating them into your workflow. Get a free copy of a Nature Protocols wallchart outlining the production of therapeutic CAR T cells. The Immunology Science Round Up Maternal Vaccine Against GBS – A Phase I/II trial shows that a maternal hexavalent Group B Streptococcus vaccine is safe and elicits robust antibody responses in both mothers and infants. Decoding Treg Differentiation – TCR specificity and antigen presentation context determine regulatory T cell differentiation and phenotype, providing a framework for antigen-specific immune tolerance. A Microbiota–Autoimmunity Axis – Disrupted dendritic cell development promotes gut dysbiosis that drives inflammatory dendritic cell expansion and systemic autoimmunity. Programming Regulatory T Cells – Arginine availability regulates MHC class I antigen presentation, influencing antiviral immunity and cancer development. Image courtesy of Dr. Pere Santamaria. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy's (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL).After a brief overview of progress in the cellular therapy field and pediatrics' first and only FDA approved CAR T product since 2017, their discussion explored the following:Review of real-world practice and outcomes in ALLPediatric practical challenges including logistics, leukapheresis, and lymphodepletion chemotherapyStrategies for managing cell therapy toxicities in pediatricpatientsConsiderations for survivorship and long-term toxicitiesGaps in pediatric care and future directionsListen below or via your favorite podcast platform.ReferenceO'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035

The Tim Corrimal Show Episode 844 – August 9, 2026 On episode 844 of The Tim Corrimal Show, I am joined at the round table with Joe (Joseph Santorsa on Facebook and @marnus3.bsky.social on BlueSky) and Cathy (@cathylarkin.bsky.social on BlueSky) and from the Let's Remember To Never Forget Facebook Page. On the show this week we […] The post Episode 844 – I Don't Want to go on the Cart first appeared on The Tim Corrimal Show.

Medical breakthroughs rarely happen overnight. They begin with an idea, grow through years of research, and eventually reach the patients whose lives they may change. Andrea Lopez has spent her career helping make that journey possible. In this week's Celebrate Your Story, Andrea shares how a childhood fascination with medicine led her from Ecuador to New York, where a professor's encouragement opened the door to a career in cancer research. Today, she works at the forefront of CAR T-cell therapy, helping hospitals deliver treatments that harness a patient's immune system to fight cancer. Our conversation explores what it takes to turn a scientific discovery into a life-changing therapy and how AI is giving researchers new tools to understand complex data. Andrea also reflects on the mentors who shaped her career and explains why she believes the best leaders recognize potential in others before those individuals recognize it themselves. If you've ever wondered what happens between a breakthrough in the laboratory and a treatment in the hospital, you'll come away from this episode with a deeper appreciation for the people whose work is quietly reshaping the future of medicine.  

Catching up with the Discord! NBA equivalents for our favorite college basketball teams! Superlatives using Jeff Borzello's top 25! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Don't have time to listen to the entire Dave & Chuck the Freak podcast? Check out some of the tastiest bits of the day, including chuck's new album songs of Cart-Man, a fart forces people to leave the new Spiderman movie and so much more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression. Key topics included: The current treatment algorithms for late relapse refractory multiple myeloma The significance of antigen expression in guiding treatment decisions The role of bispecific antibodies like teclistamab and talquetamab Managing side effects and improving patient quality of life The importance of collaboration between community hematologists and tertiary care centers Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Subscribe for more insights and updates on oncology treatments! #MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

Welcome back to Not A Bomb, the podcast where we resurrect cinema's most infamous box office disasters and ask the burning question: is it a bomb? This week, Troy and Brad strap into the chaotic, nitro‑fueled world of the 2001 racing epic Driven. And before we go any further, yes, Troy is back from surgery and only slightly a little high on pain medication, which honestly might be the perfect state of mind for revisiting a movie this unintentionally wild.Driven arrived during the era when Hollywood believed the cure for every script problem was “more CGI, more speed, more Stallone.” The film promised high‑octane racing, intense rivalries, and behind‑the‑scenes drama in the world of CART. What audiences got instead was a dizzying mix of digital car mayhem, melodramatic speeches, and physics‑defying crashes.Troy and Brad dig into the film's over‑the‑top action sequences, the baffling script choices, and one of the worst displays of “acting” this podcast has ever seen…. cough, cough - KIP! They also explore how the film's reputation has evolved, why some viewers have embraced its unintentional charm, and whether Driven deserves a second look or remains a cautionary tale about letting Stallone write his own sports movies.Buckle up, avoid the flying manhole covers, and prepare for a ride that makes absolutely no sense. This is one cinematic spinout worth revisiting.Want to help support the show? Head over to the Not A Bomb Tee Public store and check our merchandise. Special thanks to Ted Blair for the amazing designs!We're committed to hearing your feedback and suggestions. If there's a cinematic flop you'd like us to delve into, please reach out to us at NotABombPod@gmail.com or through our contact page. Your reviews and feedback are what drive us. If you enjoy our content, consider leaving a review on Apple Podcast or Spotify.Cast: Brad, Troy

This month, the gals are joined by fellow podcaster and friend IRL Aaron Schoenrock to discuss clumsy robots, spilled hot sauce, Ohio's most awkward Chili's, nasty pro athletes, cadaver otters, and the grouchiest kitty in all of heaven. Tune in for July's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Originally aired 2/7/2023Introducing ZOUK'S CUBES – a new podcast from the creators of Add to Cart! Jason Mantzoukas is taking over the feed to bring Ku and Su on an unforgettable journey into the world packing cubes, pouches and backpacks. It's a meeting of the minds for Kulap, as her two besties Jason and SuChin hit it off at first, thanks to their shared love of wool socks and arch support. But things take a quick turn when Zouk's gear threatens the chaos Su thrives on. Forget everything you've heard so far, this is episode zero. Please note, Add To Cart contains mature themes and may not be appropriate for all listeners. To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below. Jason and Su share a deep love of Darn Tough SocksThe Birkenstock Zermatt slipper is so good, Jason bought severalThese small bags from Tom Bihn and Evergoods make going through TSA a breezeThis Evergoods backpack is carry-on and under-the-seat sizeBut wait, there's more backpacks: bellroy's Transit Backpack, and the Synik 30 and Shadow Guide 33 from Tom BihnThis Nitecore Powerbank can charge Jason's phone three times in one goThe stars of Zouk's Cubes are these Peak Design Packing CubesThe cherry on top of Jason's organizational system: little plastic baggiesCan't stand the Monopoly board game? Try the card game (pst, get the green pack)Jason nerds out about the Star Wars: Thrawn Series (and the Audible version too)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sam Harris speaks with Siddhartha Mukherjee about the science of cancer. They discuss the updated edition of The Emperor of All Maladies, whether cancer is one disease or many, why prevention is so hard, inflammation and air pollution as carcinogens, the myth that cell phones cause cancer, liquid biopsies and Bayesian reasoning, immunotherapy and CAR T cells, drug pricing, the promise of AI in drug discovery, the state of American medical science, and other topics. If the Making Sense podcast logo in your player is BLACK, you can SUBSCRIBE to gain access to all full-length episodes at samharris.org/subscribe.